Tavapadon

N/A

Report date: 2025/09/28 11:10:40
NME

Base Information

Drug NameTavapadon
Drug Alias NamePF-06649751CVL-751PF-6649751
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D5 receptor agonistsDopamine D1 receptor agonists
TargetsDopamine D1 receptorDopamine D5 receptor
Therapy Area/IndicationsRenal InsufficiencyParkinson DiseaseHepatic Insufficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[19] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesPfizer IncCerevel Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesCerevel Therapeutics LlcAbbvie Inc
Inactive CompaniesPfizer Inc
Active IndicationsRenal InsufficiencyParkinson DiseaseHepatic Insufficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A